CKD Biomarkers Consortium Overview
Scientific inquiry into the causes and consequences of chronic kidney disease (CKD) has been hampered by a dearth of blood and urinary markers that predict or reflect disease progression. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the CKD Biomarkers Consortium to promote the discovery and validation of biomarkers to advance the field of CKD research. The NIDDK CKD Biomarkers Consortium brings together investigators whose expertise includes clinical nephrology, epidemiology, molecular biology, genomics, proteomics, metabolomics, systems biology, laboratory medicine, biostatistics, and laboratory test verification and qualification.
CKD is a major public health problem in the United States that is increasing. The prevalence of CKD has risen over the past two decades to 11.5% of the U.S. population. CKD is a life‐course disease that typically evolves over many years, with a long latent interval when the disease is clinically silent, and usually detected only with use of diagnostic tests. Currently, clinical detection and management of kidney disease is primarily performed using a set of biomarkers that assess kidney function. While the biomarkers that are currently utilized are essential parts of routine clinical practice and research, they do have important limitations. The CKD Biomarkers Consortium will pursue the development and validation of novel biomarkers for CKD by assaying biological specimens and utilizing data from the nation’s largest epidemiological studies of kidney disease.
Collaborations with the CKD Biomarkers Consortium
Investigators interested in collaborating with the CKD Biomarkers Consortium should contact:
Krista Whitehead, MS
Research Project Manager
The University of Pennsylvania